Lexaria Bioscience Corp. Warrant (LEXXW)

The share price of Lexaria Bioscience Corp Warrant (LEXXW) is $0.30 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Lexaria Bioscience Corp Warrant (LEXXW) has given a return of -33.8% in the last 3 years.

Lexaria Bioscience Corp Warrant (LEXXW) has a market capitalisation of $ 34 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lexaria Bioscience Corp Warrant (LEXXW) and enter the required number of quantities and click on buy to purchase the shares of Lexaria Bioscience Corp Warrant (LEXXW).

Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

The CEO & director of Mr. Christopher A. Bunka. is Lexaria Bioscience Corp Warrant (LEXXW), and CFO & Sr. VP is Mr. Christopher A. Bunka.

There is no promoter pledging in Lexaria Bioscience Corp Warrant (LEXXW).

Some of the close peers are:

No, TTM profit after tax of Lexaria Bioscience Corp Warrant (LEXXW) was No Profit.